Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCI | P41743 | 4/20 | 0.42 |
| ▸ | AXL | P30530 | 2/20 | 0.42 |
| ▸ | NUDT1 | P36639 | 3/20 | 0.36 |
| ▸ | JAK3 | P52333 | 4/20 | 0.34 |
| ▸ | JAK2 | O60674 | 3/20 | 0.34 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.34 |
| ▸ | KDR | P35968 | 2/20 | 0.34 |
| ▸ | AURKA | O14965 | 2/20 | 0.34 |
| ▸ | IGF1R | P08069 | 2/20 | 0.34 |
| ▸ | DYRK1B | Q9Y463 | 2/20 | 0.34 |
| ▸ | IKBKB | O14920 | 1/20 | 0.34 |
| ▸ | CHUK | O15111 | 1/20 | 0.34 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.34 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.34 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.34 |
| ▸ | PAK4 | O96013 | 1/20 | 0.34 |
| ▸ | CSF1R | P07333 | 1/20 | 0.34 |
| ▸ | RET | P07949 | 1/20 | 0.34 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.34 |
| ▸ | PRKACA | P17612 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4352565 | 0.69 | NUDT1 (0.47) | PRKCIAXLNUDT1JAK3JAK2 | |
| SCHEMBL2318359 | 0.69 | CCNK (0.46) | PRKCIAXLNUDT1JAK3JAK2 | |
| SCHEMBL1933750 | 0.68 | PRKCI (0.42) | PRKCIAXLNUDT1JAK3JAK2 | |
| SCHEMBL14697441 | 0.67 | CCR8 (0.52) | PRKCIAXLNUDT1JAK3JAK2 | |
| SCHEMBL2223296 | 0.67 | PRKCI (0.44) | PRKCIAXLNUDT1JAK3JAK2 | |
| SCHEMBL19743086 | 0.67 | PRKCI (0.41) | PRKCIAXLNUDT1JAK3JAK2 | |
| SCHEMBL17353634 | 0.64 | PRKCI (0.42) | PRKCIAXLNUDT1JAK3JAK2 | |
| SCHEMBL29588095 | 0.64 | PRKCI (0.42) | PRKCIAXLNUDT1JAK3JAK2 | |
| SCHEMBL2320197 | 0.64 | PRKCI (0.33) | PRKCIAXLJAK3JAK2AURKB | |
| SCHEMBL2316792 | 0.63 | JAK2 (0.45) | PRKCIAXLJAK3JAK2AURKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10266532-B2 | Tricyclic modulators of TNF signaling | ABBVIE INC. (US) | 2019-04-23 | — | — | US | claimed |
| US-20230364135-A1 | GUT-SELECTIVE SEQUESTERING AGENTS FOR THE TREATMENT AND PREVENTION OF AUTISM AND RELATED DISORDERS | AXIAL BIOTHERAPEUTICS, INC. (US) | 2023-11-16 | — | — | US | disclosed |
| WO-2023154966-A1 | COMPOSITIONS AND METHODS FOR SEQUESTERING METABOLITES IN THE GASTROINTESTINAL TRACT | AXIAL THERAPEUTICS, INC. (US) | 2023-08-17 | — | — | WO | disclosed |
| US-20230066771-A1 | NUCLEAR RECEPTOR MODULATORS | ABBVIE INC (US) | 2023-03-02 | — | — | US | disclosed |
| EP-4008328-A1 | PRIMARY CARBOXAMIDES AS BTK INHIBITORS | AbbVie Inc. (US) | 2022-06-08 | — | — | EP | disclosed |
| US-20210179556-A1 | PRIMARY CARBOXAMIDES AS BTK INHIBITORS | ABBVIE INC. | 2021-06-17 | — | — | US | disclosed |
| US-11007219-B2 | Gut-selective sequestering agents for the treatment and prevention of autism and related disorders | AXIAL THERAPEUTICS, INC. (US) | 2021-05-18 | — | — | US | disclosed |
| US-20210130293-A1 | NUCLEAR RECEPTOR MODULATORS | ABBVIE INC (US) | 2021-05-06 | — | — | US | disclosed |
| US-20200390809-A1 | GUT-SELECTIVE SEQUESTERING AGENTS FOR THE TREATMENT AND PREVENTION OF AUTISM AND RELATED DISORDERS | AXIAL BIOTHERAPEUTICS, INC. (US) | 2020-12-17 | — | — | US | disclosed |
| US-20200368276-A1 | GUT-SELECTIVE SEQUESTERING AGENTS FOR THE TREATMENT AND PREVENTION OF AUTISM AND RELATED DISORDERS | AXIAL THERAPEUTICS, INC. | 2020-11-26 | — | — | US | disclosed |
| US-20160304517-A1 | TRICYCLIC MODULATORS OF TNF SIGNALING | ABBVIE INC. | 2016-10-20 | — | — | US | disclosed |
| EP-3013337-A1 | PRIMARY CARBOXAMIDES AS BTK INHIBITORS | Abbvie Inc. (US) | 2016-05-04 | — | — | EP | disclosed |
| US-20150005279-A1 | PRIMARY CARBOXAMIDES AS BTK INHIBITORS | ABBVIE INC. (US) | 2015-01-01 | — | — | US | disclosed |
| WO-2014210255-A1 | PRIMARY CARBOXAMIDES AS BTK INHIBITORS | ABBVIE INC. (US) | 2014-12-31 | — | — | WO | disclosed |
| US-20140349970-A1 | NOVEL TRICYCLIC COMPOUNDS | ABBVIE INC. (US) | 2014-11-27 | — | — | US | disclosed |
| US-20140315883-A1 | 6H-IMIDAZO[1,5-a]PYRROLO[2,3-e]PYRAZINE COMPOUNDS | ABBVIE INC. (US) | 2014-10-23 | — | — | US | disclosed |
| US-8785639-B2 | Substituted dihydropyrazolo[3,4-D]pyrrolo[2,3-B]pyridines and methods of use thereof | ABBVIE INC. (US) | 2014-07-22 | — | — | US | disclosed |
| US-8551981-B2 | Furo[3,2-d]pyrimidine compounds | ABBVIE INC. (US) | 2013-10-08 | — | — | US | disclosed |
| US-20120122846-A1 | FURO[3,2-d]PYRIMIDINE COMPOUNDS | ABBOTT LABORATORIES (US) | 2012-05-17 | — | — | US | disclosed |
| US-20110190489-A1 | Novel Tricyclic Compounds | ABBOTT LABORATORIES (US) | 2011-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122846-A1 | FURO[3,2-d]PYRIMIDINE COMPOUNDS | CDK2, DPYD, CDK3 | PRKCI 1043/4885AXL 652/4885NUDT1 238/4885 |
| US-20140315883-A1 | 6H-IMIDAZO[1,5-a]PYRROLO[2,3-e]PYRAZINE COMPOUNDS | IL5, IL2, IL15 | PRKCI 2514/4885AXL 2543/4885NUDT1 1094/4885 |
| US-20210179556-A1 | PRIMARY CARBOXAMIDES AS BTK INHIBITORS | BTK, SYK, MYD88 | PRKCI 227/4885AXL 97/4885NUDT1 3317/4885 |
| US-20150005279-A1 | PRIMARY CARBOXAMIDES AS BTK INHIBITORS | BTK, SYK, MYD88 | PRKCI 227/4885AXL 97/4885NUDT1 3317/4885 |
| US-20140349970-A1 | NOVEL TRICYCLIC COMPOUNDS | CCNI, IL2, IL4I1 | PRKCI 949/4885AXL 4089/4885NUDT1 2945/4885 |
| US-20160304517-A1 | TRICYCLIC MODULATORS OF TNF SIGNALING | TNF, TNFRSF1A, CD40 | PRKCI 668/4885AXL 1101/4885NUDT1 2287/4885 |
| US-10266532-B2 | Tricyclic modulators of TNF signaling | TNF, TNFRSF1A, CD40 | PRKCI 668/4885AXL 1101/4885NUDT1 2287/4885 |
| US-20110190489-A1 | Novel Tricyclic Compounds | CCNI, IL2, IL4I1 | PRKCI 949/4885AXL 4089/4885NUDT1 2945/4885 |
| US-20210130293-A1 | NUCLEAR RECEPTOR MODULATORS | NR1I2, NR1H2, NR5A2 | PRKCI 2135/4885AXL 2169/4885NUDT1 2693/4885 |
| US-20230066771-A1 | NUCLEAR RECEPTOR MODULATORS | NR1I2, NR1H2, NR5A2 | PRKCI 2135/4885AXL 2169/4885NUDT1 2693/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.